ANRO NYSE
Alto Neuroscience, Inc.
1W: -5.0%
1M: -13.1%
3M: -13.2%
YTD: +39.7%
1Y: +110.7%
$23.19
+1.08 (+4.88%)
Weekly Expected Move ±7.9%
$19
$20
$22
$24
$25
Credit Risk of going bust: lower than 60% of companies Debt: 0.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.04 (down 99.8%), Alto Neuroscience, Inc. would be worth roughly what it owes.
Total debt $7.0M against a stock market value of $910.0M.
Distance to default 6.22 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $5.4M (short-term plus half of long-term), stock volatility 78.7%; Altman Z'' 7.12. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.04 (down 99.8%), Alto Neuroscience, Inc. would be worth roughly what it owes.
Total debt $7.0M against a stock market value of $910.0M.
Distance to default 6.22 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $5.4M (short-term plus half of long-term), stock volatility 78.7%; Altman Z'' 7.12. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
4 relationships3
As Filer
counterparties named
1
As Counterparty
mentioned by others
3
Rel. Types
2021-06-23
Earliest Filing
2025-06-03
Latest Filing
acquirer: 1
partner: 1
investor: 1
Counterparties (Filed by ANRO)
3 relationshipsCompanies named in ANRO's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Chase Therapeutics Corporation | — | acquirer | Sold rights to assets related to CTC-501 and CTC-413 to Alto Neuroscience, Inc. | 2025-06-03 | View |
| Leerink Partners LLC | — | partner | Agent for the Company's ATM Offering of common stock | 2025-02-03 | View |
| K2 HealthVentures Equity Trust LLC | — | investor | Recipient of Amended and Restated Warrant and New Warrant | 2025-01-16 | View |
Mentioned As Counterparty
1 mentionsOther companies that named ANRO in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-27 | Officer/Director Change; Exhibits | View | |
| 2026-08-12 | Earnings Release; Exhibits | View | |
| 2026-07-14 | Material Agreement; Exhibits | Agreement | View |
| 2026-07-13 | Earnings Release; Other Events | View | |
| 2026-05-28 | Officer/Director Change | View | |
| 2026-05-13 | Earnings Release; Exhibits | View | |
| 2026-05-13 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-04-01 | Other Events; Exhibits | View | |
| 2026-03-16 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Other Events; Fin | Agreement | View |
| 2026-03-16 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-20 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement; Unregistered | Agreement | View |
| 2025-08-13 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View | |
| 2025-07-08 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-06-26 | Other Events; Financial Statements and Exhibits | View | |
| 2025-06-03 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Other Events; Fin | Agreement | View |
| 2025-05-14 | Results of Operations and Financial Condition; Submission of Matters to a Vote of Security Holders; | View | |
| 2025-03-20 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View | |
| 2025-02-12 | Other Events; Financial Statements and Exhibits | View | |
| 2025-02-03 | Entry into Material Definitive Agreement; Results of Operations and Financial Condition; Financial S | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR